Camrelizumab plus CAPOX with camrelizumab-based maintenance versus CAPOX alone as first-line treatment for gastric or gastro-oesophageal junction adenocarcinoma: a randomised phase 3 trial
Description
This database derives from a multicentre, randomised, open label phase 3 trial evaluating first line camrelizumab plus capecitabine and oxaliplatin with camrelizumab based maintenance versus CAPOX alone in patients with HER2-negative, unresectable locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. The shared database includes patient level analysis datasets (ADSL, ADTTE, ADAE, ADCM, ADCM_CODING, ADMH, ADSLRS, mi-CH), covering anonymised subject identifiers, demographics, baseline disease characteristics, treatment allocation and exposure, tumour response assessments, time-to-event outcomes, adverse events, medical history, and concomitant medications. The repository also contains the statistical programming code used to derive the analysis datasets and generate the main efficacy and safety results.
Files
Categories
Funders
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.